![]() | |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H28N4O3 |
Molar mass | 468.557 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin, [1] with a request for an additional clinical trial, which would take 5 years to complete. [2] Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use. [3]
Ruboxistaurin is an inhibitor of protein kinase C-beta. [4]
![]() | |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H28N4O3 |
Molar mass | 468.557 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin, [1] with a request for an additional clinical trial, which would take 5 years to complete. [2] Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use. [3]
Ruboxistaurin is an inhibitor of protein kinase C-beta. [4]